# A Phase II Trial of Neoadjuvant Treatment With PD-1 Inhibition (Nivolumab) With or Without IDO Inhibition (BMS-986205) and With or Without CTLA-4 Inhibition (Ipilimumab) in Resectable Stage III or IV Melanoma

> **NCT04007588** · PHASE2 · WITHDRAWN · sponsor: **Dana-Farber Cancer Institute**

## Conditions studied

- Melanoma Stage III
- Melanoma Stage IV

## Interventions

- **DRUG:** Nivolumab
- **DRUG:** BMS-986205
- **DRUG:** Ipilimumab

## Key facts

- **NCT ID:** NCT04007588
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2019-09-06
- **Primary completion:** 2019-12-19
- **Final completion:** 2019-12-19
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Slow accrual
- **Last updated:** 2020-02-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04007588

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04007588, "A Phase II Trial of Neoadjuvant Treatment With PD-1 Inhibition (Nivolumab) With or Without IDO Inhibition (BMS-986205) and With or Without CTLA-4 Inhibition (Ipilimumab) in Resectable Stage III or IV Melanoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04007588. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*